Karensa Douglas

Statistics

Publications

Citations

528

H-Index

Active since

2015

Affiliations

Edison Pharmaceuticals (United States)(Current)

Karensa Douglas is an author at Edison Pharmaceuticals (United States) specializing in hormone receptor-positive breast cancer therapy, er-associated degradation, and hormonal therapy.

Publications per year

2015–2018

Publications

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 247 citations · Full text

Medicine, Oncology, Pharmacology +13

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 119 citations · Full text

Medicine, Oncology, Pharmacology +15

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Mehmet Kahraman, Steven P. Govek, Johnny Nagasawa et al. · ACS Medicinal Chemistry Letters · 2018 · 76 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft

Steven P. Govek, Johnny Nagasawa, Karensa Douglas et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 46 citations

Medicine, Medicinal Chemistry, Oncology +14

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

Johnny Nagasawa, Steven P. Govek, Mehmet Kahraman et al. · Journal of Medicinal Chemistry · 2018 · 40 citations · Full text

Medicine, Oncology, Pharmacology +14

1–5 of 5